Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced that it has obtained marketing approval from the National Medical Products Administration (NMPA) for its nucleic acid detection kit for the human ALDH2 gene polymorphism, utilizing the PCR fluorescent probe method. The kit is designed for the qualitative detection of the 1510G>A polymorphism site in the ALDH2 gene from human peripheral blood DNA samples.
The ALDH2 gene, situated on chromosome 12, encodes for two isomerases: aldehyde dehydrogenase and nitrate esterase. Individuals with a mutant ALDH2 gene variant exhibit significantly reduced nitrate esterase activity, which can impact the efficacy of nitrate ester drugs, commonly prescribed for angina and vasodilation. Therefore, prior to nitroglycerin administration, it is advisable for patients to undergo ALDH2 gene testing to ensure the medication’s effectiveness.
Recent research has also linked the ALDH2 gene to an increased risk of various cardiovascular diseases, including heart failure, myocardial infarction, and ischemia-reperfusion injury, as well as certain cancers such as esophageal, oropharyngeal, and gastric. The detection of ALDH2 gene polymorphisms can offer insights into an individual’s alcohol metabolism capabilities. By identifying these genetic variations, Sansure Biotech’s product can aid in the clinical assessment of nitroglycerin treatment outcomes, evaluate alcohol metabolism, inform cardiovascular disease risk, and support personalized and precise diagnostic and treatment approaches, as well as guide healthy lifestyle and dietary adjustments. – Flcube.com
